 The FDA has accepted Verrica Pharmaceuticals Incs NASDAQ: VRCA resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum molluscum, a common, highly contagious skin disease. The assigned Prescription Drug User Fee Act PDUFA goal date is May 24, 2022. 